U017 Beyond the Surgery: Advances in Cutaneous SCC Risk Stratification
DESCRIPTION
There is an increased focus on risk stratification in the cSCC population due to rising incidence. Staging systems such as BWH, and NCCN guidelines have been labeling patients as high or very high risk for recurrence/metastasis based on clinical-pathological risk factors. Publications suggest that nomograms and molecular tests that can assist and add to NCCN and BWH staging. These tools can also aid clinicians in therapeutic decision making for modalities such as immune therapy and radiation.
LEARNING OBJECTIVES
Review recent literature showcasing enhanced risk stratification in cSCC
Review literature supporting treatment decision making in cSCC
Apply these learnings to sample patient cases.
DIRECTOR
Gaurav Singh, MPH, MD, FAAD
SPEAKERS
Shadi Khalil, MD, PhD, FAAD
Stanislav Nickolaevich Tolkachjov, MD, FAAD
DISCLOSURES
Shadi Khalil, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Gaurav Singh, MPH, MD, FAAD
Castle Biosciences – Speaker(Honoraria); DermaSensor Inc – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Speaker(Honoraria); Teladoc Health, Inc. – Consultant (1099 relationship)(Other Financial Benefit);
Stanislav Nickolaevich Tolkachjov, MD, FAAD
Boehringer Ingelheim – Speaker(Honoraria); Castle Biosciences – Speaker(Honoraria); Kerecis Limited – Speaker(Grants/Research Funding); Leo Pharma – Speaker(Honoraria);